FDA Approves First Medication For Common Form Of Liver Inflammation
The medication activates a thyroid hormone receptor in the liver to help reduce fat accumulation.
The FDA has approved the first medication for a common form of liver inflammation.
‘Rezdiffra’ would be used to treat nonalcoholic steatohepatitis, also known as ‘NASH,’ which happens when the liver becomes inflamed due to excess fat cells.
The medication activates a thyroid hormone receptor in the liver to help reduce fat accumulation.
It would be taken daily by mouth and approved for people who have NASH with moderate to advanced fibrosis.
The medication is also intended to be used along with a healthy diet and exercise.
Manufacturer Madrigal Pharmaceuticals expects Rezdiffra to be available next month after completing a post-approval study to verify the drug’s clinical benefit.
